Is 6681.HK overvalued or undervalued?

6681.HK currently has a P/E ratio of -3.16. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy BrainAurora Medical Technology Limited stock?

BrainAurora Medical Technology Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 6681.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 6681.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 6681.HK to protect their purchasing power. Because 6681.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 6681.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 6681.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 6681.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks6681.HK

BrainAurora Medical Technology Limited

HK$0.96-HK$0.07-6.80%

HKSE / HKD

Market cap

HK$1.3B

P/E

-3.2

EPS (TTM)

HK$-0.03

Dividend yield

0.00%

Beta

2.01

1Y return

-88.97%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$361,8172021

$2M2022

$9M2023

$17M2024

$31M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity1.33Moderate
Current ratio2.31
Cash ratio1.59
Net margin-134.4%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

6681.HK-3.2
Healthcare sector median26.8
S&P 50022.0

Trades about 112% below its sector, cheaper than its peers on earnings.

Ratios

PEG0.12
Price to book2.62
EPS (TTM)HK$-0.03
Payout ratio0%
FCF yield-3.05%

Range & risk

HK$0.95HK$9.65

Trading in the lower third of its 52-week band

Beta2.01

Profile

What BrainAurora Medical Technology Limited actually does

BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. The company develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Basic Cognitive Testing Software, an assessment of patients for basic cognitive capacity; Cognitive Ability Supplemental screening and assessment software, a solution designed to facilitate healthcare professionals assessment of patients; and Dyslexia Supplemental Screening and Assessment Software, a solution designed to facilitate the assessment of risk of developmental dyslexia in children. It also develops covid-19 induced cognitive impairment assessment and recovery training software; ADHD assessment and treatment software; quantitative cognitive assessment software for depression; depression treatment software; and cognitive impairment assessment software and cognitive impairment treatment software solutions. In addition, the company provides marketing services. BrainAurora Medical Technology Limited was founded in 2012 and is headquartered in Shaoxing, China.

CEO

Long Jun Cai

Employees

165

Headquarters

Shaoxing, ZH

Founded

2025-01-08

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 6681.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

6681.HK has a beta of 2.01, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

BrainAurora Medical Technology Limited